A U.S. federal judge has temporarily halted Louisiana’s lawsuit seeking to curb nationwide access to the abortion pill mifepristone, pending a safety review by the U.S. Food and Drug Administration. U.S. District Judge David Joseph ruled that the case should not proceed until the FDA completes its ongoing evaluation of the drug’s safety and regulatory framework. The lawsuit challenges a 2023 rule allowing mifepristone to be distributed by mail, a move that significantly expanded access to medication abortion.
Judge Joseph, an appointee of Donald Trump, emphasized that an evidence-based review by the FDA was in the public interest rather than immediate judicial intervention. While denying Louisiana’s request to block the rule for now, he indicated the state could revisit its plea once proceedings resume. Louisiana Attorney General Liz Murrill announced plans to appeal the decision, signaling continued legal battles over abortion access. The dispute follows earlier rulings by the U.S. Supreme Court, which dismissed similar challenges on procedural grounds without addressing the substance.
The case is part of a broader national conflict over abortion rights following the Supreme Court’s 2022 rollback of constitutional protections. Medication abortion—using mifepristone alongside misoprostol—now accounts for a majority of abortions in the United States, intensifying legal scrutiny. Pharmaceutical companies GenBioPro and Danco Laboratories, which manufacture the drug, have defended its safety in court filings, while multiple Republican-led states continue to pursue parallel legal challenges against federal regulations governing its use.
Pic Courtesy: google/ images are subject to copyright
